Use of dong qual (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer:: is it appropriate?

被引:27
|
作者
Lau, CBS [1 ]
Ho, TCY [1 ]
Chan, TWL [1 ]
Kim, SCF [1 ]
机构
[1] Chinese Univ Hong Kong, Sch Pharm, Shatin, Hong Kong, Peoples R China
来源
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2005年 / 12卷 / 06期
关键词
Angelica sinensis; dong quai; breast cancer; estrogen receptor; menopause; herbal therapy;
D O I
10.1097/01.gme.0000184419.65943.01
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Regarding the growing use of alternative therapies for peri- or postmenopausal symptoms, we evaluated the effect of a water extract of Angelica sinensis (dong qual), used for peri- or postmenopausal relief, on the proliferation of estrogen receptor-positive (MCF-7) and negative (BT-20) breast cancer cells in vitro. Design: The present study was designed to investigate the growth-modulating effect of dong quai water extract, alone or in the presence of 17 beta-estradiol and 4-hydroxytamoxifen, on MCF-7 and BT-20 cell cultures using MTT proliferation assay. Results: The water extract of dong quai dose-dependently and significantly stimulated the proliferation of MCF-7 cells with a weak estrogen-agonistic activity in the presence of 17 beta-estradiol, as evidenced by the significant suppression by 4-hydroxytamoxifen. Meanwhile, the extract significantly exerted a growth-stimulating effect on BT-20 in a dose-dependent manner with or without 17 beta-estradiol. No obvious difference was found in the growth of BT-20 cells treated with the extract in the presence of 17 beta-estradiol or 4-hydroxytamoxifen. Conclusions: The water extract of dong quai stimulated the growth of MCF-7 cells, possibly dependent of weak estrogen-agonistic activity, and augmented the BT-20 cell proliferation independent of estrogen receptor-mediated pathway. The present study provides data regarding the estrogen-like activity of dong quai, which might assist in decision making on herbal therapy use by women at risk for both estrogen-sensitive and insensitive breast cancer. Because of the lack of clinical data demonstrating the potential side effects of dong quai, its use in herbal preparations for the treatment of peri- or postmenopausal symptoms, especially in women with breast cancer, warrants caution pending further study.
引用
收藏
页码:734 / 740
页数:7
相关论文
共 50 条
  • [21] Letrozole - A pharmaccleconomic review of its use in postmenopausal women with breast cancer
    Dunn, Christopher
    Keam, Susan J.
    PHARMACOECONOMICS, 2006, 24 (05) : 495 - 517
  • [22] Exemestane - A review of its use in postmenopausal women with advanced breast cancer
    Clemett, D
    Lamb, HM
    DRUGS, 2000, 59 (06) : 1279 - 1296
  • [23] Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women
    Kao, YC
    Okubo, T
    Sun, XZ
    Chen, S
    ANTICANCER RESEARCH, 1999, 19 (3A) : 2049 - 2056
  • [24] Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer
    Dibi, Raquel P.
    Zettler, Claudio G.
    Pessini, Suzana A.
    Ayub, Alice V.
    de Almeida, Suzane B.
    da Silveira, Gustavo P. G.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2009, 16 (02): : 293 - 300
  • [25] Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women
    Manon Cairat
    Marie Al Rahmoun
    Marc J. Gunter
    Pierre-Etienne Heudel
    Gianluca Severi
    Laure Dossus
    Agnès Fournier
    BMC Medicine, 19
  • [26] Estrogen–progestin use and breast cancer characteristics in lean and overweight postmenopausal women
    Olof J. Kjartansdottir
    Lara G. Sigurdardottir
    Elinborg J. Olafsdottir
    Jon G. Jonasson
    Giske Ursin
    Laufey Tryggvadottir
    Breast Cancer Research and Treatment, 2017, 163 : 363 - 373
  • [27] Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women
    Cairat, Manon
    Al Rahmoun, Marie
    Gunter, Marc J.
    Heudel, Pierre-Etienne
    Severi, Gianluca
    Dossus, Laure
    Fournier, Agnes
    BMC MEDICINE, 2021, 19 (01)
  • [28] Estrogen Receptor Modulators and Down RegulatorsOptimal Use in Postmenopausal Women With Breast Cancer
    Christa K. Baumann
    Monica Castiglione-Gertsch
    Drugs, 2007, 67 : 2335 - 2353
  • [29] Estrogen-progestin use and breast cancer characteristics in lean and overweight postmenopausal women
    Kjartansdottir, Olof J.
    Sigurdardottir, Lara G.
    Olafsdottir, Elinborg J.
    Jonasson, Jon G.
    Ursin, Giske
    Tryggvadottir, Laufey
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (02) : 363 - 373
  • [30] Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy
    Li, Hongjin
    Sereika, Susan M.
    Marsland, Anna L.
    Conley, Yvette P.
    Bender, Catherine M.
    JOURNAL OF CLINICAL NURSING, 2019, 28 (23-24) : 4560 - 4571